Regarding targeting lipid catabolism, Etomoxir, one of the first CPT1 inhibitor, proved to be synergistic with many anticancer therapies [97,100,101,102,103]; Likewise, the SCD1 inhibitor, g-PPT, which reduces the synthesis of polyunsaturated fatty acids, inhibits TG synthesis and lipid droplet accumulation in cancer cells. Here, CPT1A is linked to cancer.